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ABSTRACT
Burkholderia pseudomallei (B. pseudomallei), a
causative agent of an emerging infectious
disease melioidosis, is endemic in the tropical
regions of the world. Due to increased
international travel, the infection is now also
seen outside of the tropics. The majority of
patients with identified risk factors such as
diabetes mellitus, heavy alcohol use,
malignancy, chronic lung and kidney disease,
corticosteroid use, thalassemia, rheumatic heart
disease, systemic lupus erythematosus and
cardiac failure acquire this organism through
percutaneous inoculation or inhalation. The
clinical manifestations are variable, ranging
from localized abscess formation to septicemia.
Melioidotic bone and joint infections are rarely
reported but are an established entity. The knee
joint is the most commonly affected joint in
melioidosis, followed by the ankle, hip and
shoulder joints. Melioidosis should be in the
differential diagnosis of bone and joint
infections in residents or returning travelers
from the endemic area. Melioidosis diagnosis is
missed in many parts of the world due to the
lack of awareness of this infection and limited
laboratory training and diagnostic techniques.
It also mimics other diseases such as
tuberculosis. Delay in the diagnosis, or the
initiation of appropriate and effective
treatment against melioidosis, could worsen
the outcome. Initial therapy with ceftazidime,
or carbapenem with or without cotrimoxazole is
recommended, followed by the oral eradication
therapy (based on the antimicrobial
susceptibility) with amoxicillin/clavulanic acid
or cotrimoxazole. Surgical intervention remains
important. This paper reviews current literature
on the epidemiology, clinical features,
diagnosis, and management of melioidotic
bone and joint infections.
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INTRODUCTION
Burkholderia pseudomallei (B. pseudomallei) is a
causative agent of a severe and fatal infectious
disease which is called melioidosis. B.
pseudomallei, a Gram-negative bacterium, is a
water and soil pathogen in Eastern Asia and
Northern Australia. Melioidosis has emerged as
an important cause of morbidity and mortality
for the last several decades in the Southeast
hemisphere. Melioidosis has expanded its
occurrence from the tropics to other parts of
the world such as other Asian regions,
South America and the Caribbean [1–5].
B. pseudomallei can infect healthy individuals, but
it is seen more commonly in patients with
co-morbidities such as diabetes mellitus,
malignancy and immunosuppression. Clinical
manifestations of melioidosis range from latent
infection, localized cutaneous lesions, sub-acute
pneumonia, bone and joint infections,
abscesses in body organs and cranial abscesses
to life-threatening septicemia [1, 3, 6, 7].
The clinical presentations of bone and joint
infections due to B. pseudomallei are
indistinguishable from other infectious causes.
Melioidosis should be considered in the
differential diagnosis in patients from the
disease endemic area, or who are returning
from these areas. Early diagnosis can be made
using the laboratory and clinical parameters to
prompt administration of appropriate
antimicrobial therapy, and achieve better
prognostic outcome [5]. Mortality in acute
severe melioidosis even with appropriate
treatment still remains considerably high,
ranging from 30% to 47% [8]. This article
reviews the microbiology, epidemiology,
clinical features, diagnosis, management and
aspects of melioidosis particularly associated
with bone and joint infections. This article is
based on previously conducted studies and does
not involve any new studies of human or
animal subjects performed by any of the
authors.
MICROBIOLOGY
Burkholderia pseudomallei, previously known
as Pseudomonas pseudomallei, is an aerobic,
motile, non-spore forming, intracellular, soil
saprophyte which can be found in wet soil and
surface water [9, 10]. It is an oxidase-positive,
Gram-negative bacillus with bipolar staining,
(appears as a safety pin in the Gram stain film)
which grows easily on commonly used media in
the microbiology laboratory at 37 C. Variation
in the colonial morphology can be noted;
smooth colonies appear in young culture,
while wrinkled and dry colonies appear in old
culture [11, 12]. B. pseudomallei is able to resist
hostile conditions such as extreme temperature,
nutrient deficiency, acidic and alkaline
conditions, dehydration and antiseptics and
disinfectants [11, 12]. B. pseudomallei is
resistant to different groups of antibiotics, for
example, aminoglycosides, penicillins,
cephalosporins (first and second generations),
and rifamycins.
EPIDEMIOLOGY
Melioidosis was first diagnosed in intravenous
morphine users with septicemia in Burma (now
Myanmar) in 1912 by Whitmore and
Krishnaswami [13]. The majority of cases are
reported from Southeast Asia and Northern
Australia, corresponding to tropical latitudes
between 20N and 20S, and sporadic cases have
been reported from Malaysia, Pakistan,
Indonesia, Japan, Bangladesh, India, Sri Lanka
and Indonesia [3, 14–16]. It is thought that B.
pseudomalleimay be brought up from a clay
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layer and distributed in the environment during
the rainfall, as it resides in the clay layer
25–30 cm underneath the soil surface [17–19].
Between 75% and 85% melioidosis cases from
northeast Thailand and northern Australia
occur during the wet season [18]. One study
from Malaysia reported that 57% of melioidosis
cases occurred during the rainy season, which
usually takes place every year between October
and April [20]. It is thought that there may be a
shift from inoculation to inhalation of B.
pseudomallei during the monsoon stormy
weather, hurricanes, typhoons and cyclones,
as pneumonia is a predominant presenting
feature in melioidosis [21].
Bone and joint infections due
to B. pseudomallei are a well-recognized entity
of this disease. The majority of the melioidotic
bone and joint infections are found in the case
reports from different regions of the world [5].
One study [22] from an endemic area in
Northern Australia reported a 7.6% incidence
of bone and joint infections in melioidosis
patients, which was much less than a
melioidosis case series of bone and joint
infections from Thailand (14–27% incidence)
[4, 23, 24]. A total of 29% patients with
melioidosis in Brunei had bone and joint
infections [5].
MODES OF TRANSMISSION
Hematogenous spread after percutaneous
inoculation is thought to be an important
mode of transmission in bone and joint
infections. The organism may also reach
directly from other organs, or from soft tissue
infection over bones or joints. Septic arthritis
and osteomyelitis, one or both, can be the
primary manifestation in patients with
melioidosis. Other important routes of spread
of melioidosis are ingestion and inhalation
especially during heavy rainfall and cyclones
[4, 25].
RISK FACTORS
A number of environmental and patient-related
host factors have been defined in several studies
from the endemic areas. Many cases have been
linked to occupational and recreational
exposure to surface water, for example, in rice
paddy farmers in Thailand, [26] and outdoor
work, landscaping and gardening in Australia
[22]. Melioidosis usually affects patients with
underlying illnesses such as diabetes mellitus,
heavy alcohol consumption, chronic lung
disease, renal disease, malignancy,
corticosteroid use, thalassemia, previous
trauma, rheumatic heart disease and/or cardiac
failure, and surgery [4, 22, 27–29]. Other risk
factors include splenectomy, aplastic anemia,
cystic fibrosis, glucose 6 phosphate
dehydrogenase deficiency, and systemic lupus
erythematosus (SLE) [1]. Diabetes mellitus is the
most important predisposing risk factor, and it
increases the risk of melioidosis by 100-fold [19,
22, 23, 29]. The underlying comorbidities lead
to immune dysfunction such as impaired
polymorphonuclear phagocyte functions, so
impaired phagocytic cells fail to clear this
organism. It is thought that the immune
deficiency increases the risk of melioidosis [30,
31]. One study reported that there is a 5.7 times
higher risk of septic arthritis in melioidotic
patients with diabetes mellitus, SLE and chronic
renal failure [24]. Melioidosis in bone and joint
infection is more common in males [4, 23]. This
may be the case because males are exposed to B.
pseudomallei while working in the rice paddies
and they may be more involved in other
outdoor activities.
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CLINICAL FEATURES
Melioidotic bone and joint infections remain
uncommon and are usually difficult to
differentiate from other causative agents such
as Staphylococcus, Streptococcus and others,
unless microbiologically proven in cultures.
Acquisition in bone and joint infections is
usually via direct spread through small skin
abrasions, wound infections and abscess or
hematogenous spread in patients who
presented with another primary diagnosis,
such as pneumonia or septicemia. There is no
specific clinical presentation, and it mimics
different forms of osteomyelitis, septic arthritis
infections and rheumatoid disorders.
Prominent features in septic arthritis are
swelling, tenderness, redness, and heat around
joints [21, 24]. In melioidotic bone and joint
infections, the presentation picture is usually
chronic in nature, such as persistent fever rather
than shock or respiratory failure, and overall
mortality is low in this group [23]. Either single
or multiple bone or joint involvement is
observed in the past in musculoskeletal
infections due to melioidosis. B.
pseudomalleimainly causes infections in knee
and hip joints (Table 1). It also affects the
shoulder and other joints. Increased vascular
supply in the metaphyseal regions of long bones
helps it spread easily to bones and joints.
One recent study [32] from Australia revealed
that 25.4% patients (16/63 episodes) and 31.7%
patients with melioidosis (20/63 episodes)
presented with septic arthritis and
osteomyelitis as the primary illness,
respectively. More than one focus of infection
was present in more than half of the patients
(32/50). In this study, knee (15), tibia (11) and
ankle (11) joints were the most affected,
followed by metatarsal (4), femur (3), and
lumbar spine (3) (Table 1). Teparrakkul et al.
[23] from Thailand reported that of 679
patients, 98 had musculoskeletal melioidosis.
Among joints, knee joints (41 patients) were the
most affected joint; followed by ankle (20), hip
(15), and shoulder (10) joints. Among bones,
the femur and tibia were more involved than
upper limb bones. This study also showed three
patients suffering with discitis. The high
incidence of knee joint involvement was
recorded in these two studies [23, 32]. On the
contrary, Kosuwon et al. [24] reported the
shoulder joint being more commonly infected
by B. pseudomallei. Morse et al. [4] from
Northern Australia presented a 20-year study
of osteomyelitis and septic arthritis due to B.
pseudomallei, in which 41/536 patients with
melioidosis had suffered with osteomyelitis or
septic arthritis. Of the 41 patients, primary
melioidosis was identified in 13 patients with
septic arthritis and 7 patients with osteomyelitis
while 14 had melioidosis of the bone/joint
secondary to primary melioidosis elsewhere.
Seven patients showed signs of both bone and
joint involvement. Saravu et al. [33] reported 25
culture-confirmed adult cases of melioidosis, of
which 48% (12/25) had osteomyelitis or septic
arthritis. This proportion was higher than the
14–33% reported in studies from Malaysia and
Thailand [23, 24, 34].
DIAGNOSIS
Lack of awareness about the disease, limited
laboratory resources to isolate the organism,
and confusion with other infectious diseases
such as Mycobacterium tuberculosis, may lead to
the misdiagnosis of melioidosis. Melioidosis is
diagnosed on the basis of the clinical and
laboratory parameters, and radiology. The
majority of patients have increased or low
white blood cell and neutrophil cell counts,
increased C-reactive protein or procalcitonin or
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erythrocyte sedimentation rate, impaired renal
or liver functions, and in some cases organ
failure. Accurate and timely diagnosis remains
crucial to initiate prompt definitive
antimicrobial therapy, to reduce the mortality.
Several factors play a pivotal role in the
laboratory diagnosis of melioidosis: (1)
collection of an appropriate sample; for
example, needle aspiration from the abscess,
such as a psoas abscess, or bone in the case of
osteomyelitis, tissue or bone in discitis, tissue
from ulcers or wounds, and blood cultures, (2)
transportation of the samples in appropriate
media, or in a sterile container, to the
microbiology laboratory without any delay, (3)
handling of the samples by trained and
experienced laboratory staff, (4) processing
using appropriate media, incubating and using
the best methods to identify this organism, (5)
use of specific antimicrobial discs which are
used as intravenous or oral therapy for the
treatment of melioidosis. Breach of any of the
above-mentioned steps may lead to low chances
of isolation of B. pseudomallei [1, 3, 35–37].
Isolation of B. pseudomallei from the clinical
specimens is considered to be the gold standard
in the diagnosis of melioidosis. Isolation of B.
pseudomallei from clinical samples is regarded as
a significant isolate. Use of selective media for
processing samples from non-sterile sites is
helpful in suppressing commensal organisms,
which otherwise can overgrow and give a
false-negative result. A modified Ashdown
media which contains colistin is currently
used in the laboratories for the isolation of
this organism [1, 36, 37]. Serology may be
helpful in cases of culture-negative results, or
in the absence of clinical samples from patients
with melioidosis. However, the serology results
should be interpreted cautiously in endemic
areas, where local populations have raised
melioidosis antibody levels. A group of
researchers from north eastern Thailand
reported that the indirect hemagglutination
assay has a 95% sensitivity but the specificity
is low (59%). In this study, patients with
bacterial infections had a high titer of 1:1280
[38]. One Malaysian group developed an
indirect immunofluorescence test using
whole-cell antigen for the detection of total
antibodies to B. pseudomallei. They found this
test quite rapid and reliable [39]. A raised B.
pseudomallei antibody titer in healthy
individuals is probably due to repeated natural
exposure to this saprophytic organism during
outdoor activities. Molecular methods, for
instance Polymerase Chain Reaction, or Pulsed
Field Gel Electrophoresis, are being employed in
the clinical and research laboratories; these are
less sensitive than gold-standard culture results
[40].
TREATMENT
Normally systemic antimicrobial therapy active
against B. pseudomallei, vigorous and repeated
washouts, and several extensive debridements
of infected bone are the cornerstones of
treatment of bone and joint infections.
Prompt administration of antibiotics remains
important to reduce morbidity and mortality.
Inflammatory markers and clinical signs of
improvement are used to gauge the response
to the specific therapy for melioidotic bone and
joint infections. Intravenous antimicrobial
therapy should be prolonged for deep-seated
infection or complicated infections from four to
eight weeks followed by the oral maintenance
therapy for a minimum of 12 weeks (Tables 2, 3)
[1, 4, 28, 31, 41]. Mortality was quite high
before the antibiotic era. In an open-labeled
randomized trial, the group compared the
efficacy of ceftazidime (120 mg/kg/day) with
24 Infect Dis Ther (2016) 5:17–29
‘‘conventional therapy’’ (chloramphenicol
100 mg/kg/day, doxycycline 4 mg/kg/day,
trimethoprim 10 mg/kg/day, and
sulphamethoxazole 50 mg/kg/day) in the
treatment of severe melioidosis. Ceftazidime
was associated with 50% (74–37%) reduction
in mortality rate than the conventional therapy
[42]. Ceftazidime has become the drug of choice
for intensive therapy after this study.
Ceftazidime, or a member of the carbapenem
group, is the drug of choice to treat this
infection, followed by oral cotrimoxazole as a
monotherapy or amoxicillin–clavulanic acid
[41, 43, 44]. On the other hand, Inglis suggests
the use of ceftazidime, meropenem or
imipenem and
trimethoprim–sulfamethoxazole and folic acid
in the acute phase followed by any two
antibiotics from the group of
trimethoprim–sulfamethoxazole, doxycycline,
and amoxicillin–clavulanic acid, as eradication
therapy in deep-seated infections [11]. One
study from Malaysia showed a low-level
resistance to the commonly used antibiotics
for the treatment of melioidosis. In this study,
all isolates (170) of B. pseudomallei appeared
Table 2 Antimicrobial therapy for treating severe melioidosis [11, 21, 32, 37, 41]
Patients Drug Dosage/route Frequency
Severe melioidosis
With no complications Ceftazidime IV 50 mg/kg/day (maximum 2 g)




bacteraemia, or in intensive care unit






















As above As above
Duration of IV antimicrobial therapy in acute phase is usually 4–8 weeks. Not less than 2 weeks from last operative
intervention
The therapy should be rationalized after the availability of culture and sensitivity results
IV Intravenous
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sensitive to meropenem and
piperacillin/tazobactam, while less than 1%
resistance was recorded in ceftazidime,
imipenem, and amoxicillin–clavulanic acid. Of
170 isolates, 98 were resistant to ciprofloxacillin
[45]. Table 1 summarizes the antibiotic therapy.
No specific vaccine is available for melioidosis.
Out-of-hospital intravenous antimicrobial
treatment in clinically stable patients, or those
who do not require intensive care support or
hospitalization, has become popular in many
parts of the world. This service saves not only
hospital bed days, and healthcare costs, but also
healthcare workers’ time. These patients are
closely monitored by specialist staff during the
treatment period [46, 47]. One study from
Southeast Asia looked at outpatient
antimicrobial therapy in 56 patients with
confirmed melioidosis who were treated in
two large tertiary care hospitals. Patients
received ceftazidime 100–200 mg/kg/day via a
peripherally inserted central catheter (PICC)
and elastomeric infuser. Eighty-six percent of
patients (47/56) completed the course. Of the
nine patients who did not complete the
therapy, four patients experienced adverse




Trimethoprim–sulfamethoxazole Adult[60 kg 160 mg/800 mg tablets; two
tablets every 12 h
For osteomyelitis: the
recommended duration is a
minimum of 6 monthsAdult,
40–60 kg
80 mg/400 mg tablets; three
tablets every 12 h
Adult,\40 kg 160 mg/800 mg tablets; one
tablet every 12 h OR
80 mg/400 mg tablets; two tablets
every 12 h
Child 8 mg/40 mg per kg; maximum







500 mg/125 mg tablets; three
tablets every 8 h
For septic arthritis: the
recommended duration is a
minimum of 3 monthsAdult,\40 kg 500 mg/125 mg tablets; two
tablets every 8 h
Child 20 mg/5 mg per kg every 8 h;
maximum dose 1000 mg/
250 mg every 8 h
OR
Doxycycline Adult 100 mg tablets, 12 hourly
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reactions, two needed surgical intervention,
and in three patients the underlying illness
worsened. The overall outcome was good [47].
RELAPSE
High relapse rates in B. pseudomallei infections
are mentioned in the literature [4, 48–50]. It
remains important to complete therapy
(Table 1), including the maintenance therapy,
to prevent relapse in melioidosis. Patients
treated with appropriate antibiotics require
long-term follow-up, as this organism remains
latent for up to 26 years in the body. One recent
study on melioidotic bone and joint infections
reported relapse in 10 patients. Of the 10
patients, seven received less than 4 weeks of
antibiotics [32]. The average time between
discharge from the hospital and relapse is
approximately 21 weeks [49]. A higher relapse
rate (30%) has been noted if the overall
duration of antimicrobial therapy is less than
eight weeks [50]. Relapse should be considered
and treated as a first episode [50].
CONCLUSION
In endemic areas, B. pseudomallei should be
considered as one of the causative agents of
bone and joint infections because of its rising
incidence and high rate of morbidity and
mortality if not diagnosed and treated early
on. A high index of suspicion of melioidosis is
required to make the diagnosis. Isolation of B.
pseudomallei from clinical specimens is
considered to be the gold standard; however,
to achieve this, samples must be processed
carefully and in the appropriate media.
Treatment of melioidosis affecting bones and
joints consists of antimicrobial therapy coupled
with surgical management including washouts
of joints and debridement of infected bone.
Those patients with deep-seated or complicated
infections require intravenous antibiotics for
4–8 weeks, followed by oral antibiotics for a
minimum of 12 weeks. Ceftazidime is usually
the intravenous antibiotic of choice, which is
followed by oral therapy such as cotrimoxazole.
Some countries are now using outpatient
antimicrobial therapy for their clinically
stable patients. Unfortunately no vaccine has
yet been developed for this disease, which
makes the awareness and understanding of
melioidotic bone and joint infections, and the
need for timely diagnosis and treatment, all the
more relevant to microbiologists today.
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